Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension
- Details
- Category: Product
Forest Laboratories, Inc. (NYSE: FRX) today announced the results of a double-blind, randomized, placebo-controlled clinical trial, published in the November 2007 issue of the Journal of Clinical Hypertension, which demonstrated that nebivolol significantly reduced sitting diastolic and systolic blood pressure used as monotherapy among African-American patients with stage I-II hypertension.
Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
- Details
- Category: Bayer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization to Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), or liver cancer. Nexavar, an oral anti-cancer drug, is the first and only approved systemic drug therapy for liver cancer and the only drug therapy shown to significantly improve overall survival in patients with the disease.
Nycomed signs definitive agreement to acquire Bradley Pharmaceuticals, Inc.
- Details
- Category: Nycomed
Nycomed today announced the entry into a definitive agreement to acquire Bradley Pharmaceuticals, Inc., a company focused on niche therapeutic markets in the USA. The acquisition will add further branded dermatologics to the PharmaDerm division of Nycomed US and will provide an enhanced platform for in-licensing and co-promotion of dermatology products. The transaction is subject to the receipt of Bradley shareholder approval and approval by competition authorities. It is expected to close in the first quarter of 2008.
Pfizer to Appeal German Court Decision in Lipitor Patent Case
- Details
- Category: Pfizer
Pfizer Inc said that the Federal Patent Court in Munich, Germany has revoked the companyâs patent covering atorvastatin calcium, the active ingredient in Lipitor. The patent at issue in the lawsuit (EP 409,281) expires in July 2010.
GSK reports third quarter EPS of 23.7p
- Details
- Category: GlaxoSmithKline
Commenting on the performance in the quarter and GSK's new Operational Excellence programme, JP Garnier, Chief Executive Officer, said: "GSK remains on track to meet its earnings guidance for the year, despite significant challenges. We continue to strengthen our product portfolio with 15 products launched, approved or filed so far this year, and we remain very focused on delivering more from our late-stage pipeline.
Bristol-Myers Squibb Company Reports Financial Results
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) reported financial results for the third quarter and nine months ended September 30, 2007 and updated earnings guidance for the full year. The company posted third quarter 2007 net sales of $5.1 billion, an increase of 22% over the same period in 2006.
Bayer Issues Additional Guidance to Physicians on Trasylol®
- Details
- Category: Bayer
Bayer announced new guidance to physicians and health care providers regarding the use of Trasylol® (aprotinin injection) in patients at an increased risk of blood loss and blood transfusion undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB).
More Pharma News ...
- One-Year Results from the Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Abbott Named to Science Magazine's List of Top Employers
- Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent
- Novartis delivers record earnings in first nine months of 2007
- Strong sales growth in the first nine months of 2007
- Pfizer Reports Third-Quarter 2007 Results
- Novel agent for treatment of cerebral stroke and other diseases with neuronal damage